While I agree with what you say, icemandios, the bureaucracy in these massive provider organizations can often limit their ability to make rapid and effective policy changes. This is one reason INO can make things happen so quickly when compared to MRK, PFE and other big pharma behemoths. Only time will tell since everyone already knows 4K is the right way to proceed forward.
Thanks for sharing this extremely relevant information, stillheretostayiloveinovio. Along the same vein as Dr. Kim, Dr. Sardesai is making every effort to explain why INO technology is the real McCoy and will revolutionize global human healthcare. It not like in 6 months anyone can claim the INO TEAM was delinquent in sharing "insider information". Thanks again.
Thanks, icemandios. I have full faith that all providers will ultimately agree it is better to support the 4K diagnostics. My experience with insurers, however, leads me to believe that it will be a lengthy approval process. I think they pattern their work process after the US legislature where almost nothing gets done.
very nice position overview, patcarr832. Thanks! I look forward to INO science minimizing the need to learn more about poker in the future. And who knows, somebody may even take the time to investigate a potential problem in locating the balance of shares.
Great question. I'm certain it is "under review" by many U.S. providers at this time. Since the new Medicare plans are currently undergoing annual enrollment, maybe there will be enough "chatter" to expedite the review process? The UK public healthcare system is a black hole to me when I try to source updates.
Thanks for posting this important INO distinction, one_for_the_money. THE INO TEAM has an impeccable game plan that will continue to add value to their efforts that will improve global healthcare.
you're being too kind, detriver50. OMG, I just at this moment correlated your own "50" with your suggestion for INO followers to get shares below $50 while you can. Guess I just saw the forest through the trees. Maybe $100 or $200 will be more appropriate at the close of the 2014 dwarfing?
lately they appear to be speechless. The INO TEAM may have too many moving parts for their "writers" to follow at this time. Thumbs down parade also seems to have subsided. Any correlation? I like the quiet and look forward to more solid INO validated reports that show continued progress toward improving global healthcare. See everyone at the NASDAQ Monday.
thanks again, Coop99man. I also sensed in Dr. Kim's voice that he was in his former "jovial" confident state of mind. Every presentation he seems to try harder and harder to educate the audience that this is the real McCoy and here's why. I liked the wide swings this week and bought more shares before the NASDAQ transition. I'm really confident that good times are ahead for all patient INO investors, especially when one considers the current absence of the silly thumbs down parade of naysayers. Congrats on persevering and beating the ID-deletion system. Thanks again and rest well.
good point, bourbon_on_my_cornflakes. I believe the NYSE has seven specialist firms while the Nasdaq has almost 300 market makers. Good all around decision by INO, IMHO.
excellent point, sand_snow. INO may have pursued the NASDAQ over the NYSE (AMEX) for the same reasons below that Facebook did so earlier. Regardless, I am confident the INO TEAM made the correct decision.
1. NASDAQ has more tech stocks than the NYSE. NASDAQ has 7 of the 10 biggest tech stocks including Apple, Google, and Microsoft. NASDAQ thus has more experience with tech stocks.
2. NASDAQ has a cheaper pricing structure than NYSE
Indeed, detriver50. I always enjoyed the well-planned, yet powerful, killing effect of Steven Segal as a navy seal when compared to the brute force imposed by Arnold as the Terminator. I can't imagine how Dr. Kim does these presentations with all the "hidden" additional positive details bottled up in this mind. His return to a much more assertive demeanor in these past two presentations is a good indication that the latest results continue to be positive.
thanks, detriver50, for posting about potential new news today. I just noticed the next show originally scheduled for Friday is now today at 4 PM PT. Was out all AM if it was posted earlier.
I agree, detriver50, that Dr. Kim once again sounded very confident. It seems he tries harder in each presentation to clearly explain to the naysayers why there is such a high probability for company success. While on the surface the presentation appeared to be nothing new, the live-time presentation dialogue by Dr. Kim said otherwise. IOW, I was very satisfied with his most recent talk. Let's see what tomorrow brings?
I remember there was talk about the reasoning behind the R/S was to avoid delisting due to failure to be compliant with listing requirements. Well, here we are several months post R/S and the current valuation is still very compliant, even with the recent decline in valuation. In fact, INO is so compliant that it will be "delisted" in order to migrate to the NASDAQ, an exchange much more consistent with INO, a company capable of significant growth. This is truly a reflection on how the INO TEAM has a long-term plan in place to assure long-term company growth. This also applies to the overall design of the many ongoing clinical trials and those planed for the near future. The value added by Roche, the first INO partner, goes well beyond the "obvious" milestones in the contract as shown by the upgraded clinical protocol designs. Bottom line is the while INO continues to gain strength as a viable company, the market continues to manipulate the perceived valuation lower. IMHO, good clinical results will eventually more clearly illustrate the true INO net worth is higher than currently perceived by the "financial" market.
Thanks for the reminder, danwebs2014. I just registered and now only wait for the slides 15 minutes before the start time.
I agree, bourbon_on_my_cornflakes. The perception of the 2 exchanges differ widely. It just seems more appropriate for INO at this stage in their development to be listed on the NASDAQ. Maybe the NYSE will eventually be more appropriate sooner than many believe possible?
NASDAQ - Exchange for high-tech stocks that are more growth oriented and potentially more volatile.
NYSE - Exchange for well-established companies, more stable stocks.
Once the application is submitted, the FDA has 60 days to conduct a preliminary review which will assess whether the NDA is "sufficiently complete to permit a substantive review". I presume OPKO will receive payment after the preliminary review confirms the "acceptance" milestone? Maybe they will receive confirmation earlier? Frost clearly touted the fact that data will be compliant. I have no reason to believe any other NDA requirements will be noncompliant. The clock is officially ticking.